Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 3 N=1,097 Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) — -5.71; -7.95; -9.35; -10.63 mmHg — p=<0.0001
N/A N=146 Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
Hypertension
Primary: Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment — -24.5; -10.3 mm Hg
Phase 2 N=189 An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Resistant Hypertension
Primary: Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours — -5.77; -6.41; -6.63; -6.66 mmHg — p=0.5651
Phase 2 N=64 Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
Patients, Resistant Hypertension
Primary: Number of Participants With Reported Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths — 12; 3; 14; 0 Participants
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
N/A N=53 Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Hypertension
Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001
N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
Phase 2 N=155 A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Hypertension
Primary: Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF) — -11.4; -13.1; -12.5; -18.7 mmHg
Phase 2 N=295 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Phase 3 N=947 Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure — -6.48; -9.24; -9.33 mmHg — p=<0.0001
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
Phase 3 N=119 The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
Arterial Hypertension · Hypertension, Resistant to Conventional Therapy · Diabetes Mellitus
Primary: Change of of Systolic Blood Pressure — -9.6; -0.7 mm Hg
N/A N=17 Controlling and Lowering Blood Pressure With The MOBIUSHD™
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
Phase 2 N=34 Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
Hypertension
Primary: Categorical Classification of Subjects Into Responders vs. Non-responders — 10; 2; 4; 19 Participants
Phase 3 N=730 A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Resistant Hypertension
Primary: Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement…
N/A N=30 Controlling and Lowering Blood Pressure With The MOBIUS HD™ (CALM-FIM_EUR)
Hypertension
Primary: Number of Participants With Serious Adverse Events (SAEs) — 8 Participants
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
N/A N=4,542 FimasaRtan-basEd BP Targets After Drug SwitcHing
Essential Hypertension
Primary: Percentage of Patients With Controlled Blood Pressure (<140/90 mmHg) — 3083 Participants
Phase 3 N=197 Telmisartan 80mg Non-responder Trial
Hypertension
Primary: Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough — 12.28; 3.14 mmHg — p=<0.0001
Phase 3 N=2,204 Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Essential Hypertension
Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187
Phase 2 N=275 A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Resistant Hypertension
Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -12.4; -17.3; -19.2; -9.8 mmHg
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
N/A N=1,247 The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension
Arterial Hypertension
Primary: The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline — 33.47 mm Hg
Phase 4 N=256 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
Essential Hypertension ( Mild to Moderate)
Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…
N/A N=265 Rheos® Pivotal Trial
Hypertension
Primary: Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood Pressure — 54.1; 46.4 percentage of participants
Phase 3 N=1,191 Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg
N/A N=17 Renal Denervation for Management of Drug-Resistant Hypertension
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement) — 0.7; -21.7 mmHg — p=0.018
Phase 4 N=694 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
Essential Hypertension
Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…